Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05439603 · ClinicalTrials.gov registry record · Phase 2
ANC-501 in the Treatment of Adults With Major Depressive Disorder
A Phase 2 study of Major Depressive Disorder, sponsored by Ancora Bio, Inc. d/b/a EmbarkNeuro.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 8
- Study locations
NCT05439603 is a Phase 2 study of Major Depressive Disorder that has completed, run by Ancora Bio, Inc. d/b/a EmbarkNeuro. The registered enrollment target is 15 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT05439603, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by Ancora Bio, Inc. d/b/a EmbarkNeuro.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 8
- Study locations
Study Summary
A Phase 2 Study of ANC-501 in the treatment of adults with Major Depressive Disorder
Conditions Studied
Interventions
- DRUG ANC-501
Study Locations (8)
Florida
- Florida Behavioral Medicine - Largo
- Innovative Clinical Research, Inc. - Lauderhill
- Combined Research Orlando - Orlando
New York
- Clinilabs Drug development Corporation - New York
- Richmond Behavioral Associates - Staten Island
California
- ATP Clinical Research - Orange
New Jersey
- Clinilabs Drug Development Corporation - Eatontown
Oklahoma
- Conrad Clinical Research - Edmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-09-19 |
| Est. Completion | 2023-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05439603
The ClinicalTrials.gov registry entry for NCT05439603 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (96% lower). The listed sponsor is Ancora Bio, Inc. d/b/a EmbarkNeuro, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which ANC-501 is the first listed.
NCT05439603 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Florida, New York, California.
Frequently Asked Questions
What is clinical trial NCT05439603 about?
NCT05439603 is a clinical study titled "ANC-501 in the Treatment of Adults With Major Depressive Disorder". A Phase 2 Study of ANC-501 in the treatment of adults with Major Depressive Disorder
What is the current status of trial NCT05439603?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2022-09-19. Estimated completion is 2023-10-18.
What conditions does trial NCT05439603 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05439603?
The interventions under investigation include: ANC-501 (DRUG).
Who is sponsoring clinical trial NCT05439603?
This trial is sponsored by Ancora Bio, Inc. d/b/a EmbarkNeuro, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05439603 being conducted?
This trial has 8 study locations across California, Florida, New Jersey, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.